Barinthus Biotherapeutics (NASDAQ:BRNS) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS - Free Report) in a research note released on Friday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, Alliance Global Partners reduced their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating on the stock in a report on Tuesday, August 13th.

Barinthus Biotherapeutics Stock Down 8.3 %

Shares of NASDAQ:BRNS traded down $0.12 during trading on Friday, hitting $1.35. 43,853 shares of the company were exchanged, compared to its average volume of 23,685. Barinthus Biotherapeutics has a 1-year low of $1.11 and a 1-year high of $4.16. The company has a market capitalization of $53.22 million, a P/E ratio of -0.91 and a beta of -0.59. The business's 50 day moving average is $1.29 and its 200-day moving average is $1.57.

Barinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.23. The firm had revenue of $14.97 million during the quarter. During the same period in the previous year, the company earned ($0.37) EPS. As a group, sell-side analysts anticipate that Barinthus Biotherapeutics will post -1.71 earnings per share for the current year.

Hedge Funds Weigh In On Barinthus Biotherapeutics

Hedge funds have recently made changes to their positions in the stock. M&G Plc acquired a new stake in Barinthus Biotherapeutics during the 2nd quarter valued at approximately $7,276,000. Alphabet Inc. acquired a new stake in shares of Barinthus Biotherapeutics during the second quarter worth $2,119,000. DC Funds LP bought a new position in Barinthus Biotherapeutics during the first quarter worth $1,528,000. BlueCrest Capital Management Ltd acquired a new position in Barinthus Biotherapeutics in the first quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. bought a new stake in Barinthus Biotherapeutics during the second quarter valued at $32,000. 25.20% of the stock is currently owned by institutional investors.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.